Conference Reports for NATAP

Back

11th Workshop on Adverse Drug Reactions and Co-morbidities in HIV, Philadelphia, USA, October 26-28 2009     Omega-3 fatty acids supplementation may improve inflammation and endothelial activation in HIV-infected adults on stable antiretroviral therapy - (05/24/10)   Vitamin D and Efavirenz - (05/24/10)   Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D - (05/24/10)   Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV - Workshop report - (01/28/10)   EACS: Feedback Reports (clinical, translational) from the 11th International Workshop on Adverse Drug reactions and Co-morbidities in HIV reported at EACS 2009 Cologne - (11/20/09)   Framingham Risk and Lipoprotein Changes after 24 Weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1 Infected Subjects - (12/03/09)   Both once-daily saquinavir / ritonavir and atazanavir / ritonavir, when combined with tenofovir / emtricitabine conserve adipose tissue, only modestly affect lipids and exhibit similar mild reductions in glomerular filtration rate over 48 weeks: the BASIC trial - (10/28/09)   Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naïve HIV-1 infected patients: ARTEN Study Week 48 results - (10/28/09)   Neuropsychiatric adverse events in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 copies/mL at screening - (10/27/09)   Correlation between laboratory parameters and use or discontinuation of nucleoside analogues in the MONET trial - (10/27/09)   48 week changes in Quality of Life and adherence in the MONET trial: darunavir/ritonavir with and without nucleoside analogues for patients with HIV RNA <50 at screening - (10/27/09)